Skip to main content
TipRanks
Go Ultimate75% OFF

Madrigal Pharmaceuticals (MDGL) Q3 2026 Earnings Report

1,370 Followers

MDGL Q3 2026 EPS Results

Actual EPS
$1.83
Consensus EPS
-$0.86
Beat/Miss
Beat by +$2.69
One Year Ago EPS
-$5.08

MDGL Q3 2026 Revenue Results

Actual Revenue
$431.27M
Expected Revenue
$404.17M
Beat/Miss
Beat by +$27.10M
YoY Revenue Growth
+50.13%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
Before Open
Conference Call
Tuesday, November 3, 2026
MDGL Upcoming Earnings

Madrigal Pharmaceuticals's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

MDGL Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:-7.98%|
Earnings Call Sentiment|Positive

The call was strongly positive, driven by 50% year-over-year quarterly sales growth, more than $1.1 billion in year-to-date sales, nearly doubled active patients, accelerating MASH-market growth, the first profitable quarter, positive operating cash flow, and a broadening F4c and combination pipeline. The main challenges were elevated commercial spending and cost of sales, gross-to-net in the mid-to-high 30% range, potentially uneven near-term profitability, the event-dependent late-2027 F4c readout, and the long timeline for MAESTRO-CSPH results. Highlights significantly outweighed the lowlights.

Company Guidance

Management expects U.S. F2/F3 MASH market growth of more than 30% by the end of 2026 and said it expects to see double-digit growth for the foreseeable future; Q4 is expected to show good growth, with the consensus growth rate between Q3 and Q4 reiterated, while 2027 revenue guidance is not being provided. Gross-to-net is expected to come in at the low end of our mid-to-high 30% range for 2026, and next year is expected to be plus or minus the high end of our range that we gave this year, which was mid to high 30%; full-year 2026 R&D expenses are expected to be nominally lower than 2025, SG&A expenses are expected to increase compared to 2025, and Q4 SG&A expenses are expected to be higher than Q3. MAESTRO-NASH OUTCOMES is expected to read out in late 2027, MAESTRO-CSPH is planned to initiate in the first half of 2027 with results expected in the early 2030s, and three phase II combination trials are expected to initiate in 2027.

  • Strong Rezdiffra Revenue GrowthThird-quarter 2026 net sales were $431.3 million, up 50% year-over-year, with year-to-date net sales of $1.1 billion. Based on the quarter's results, the company is annualizing at more than $1.7 billion.
  • Rapid Patient AdoptionActive Rezdiffra patients reached more than 55,850 at the end of the third quarter, compared with more than 29,500 a year ago, representing nearly twice as many patients on therapy.
  • Accelerating F2/F3 MASH MarketThe diagnosed U.S. F2/F3 MASH population increased from 315,000 at the end of 2023 to 460,000 at the end of 2025 and to more than 530,000 as of June 30, 2026. The market is expected to grow more than 30% in 2026.
  • Significant Market RunwayThe MASH diagnosis rate and Rezdiffra market penetration are each approximately 10%, which management described as being about 1% into the total opportunity. Management expects double-digit market growth for the foreseeable future.
  • Broad Launch Execution and Prescriber ExpansionManagement said Rezdiffra has built a broad and durable prescriber base, is increasing prescribing depth, and benefits from excellent access, a differentiated profile, and strong patient adherence. The company has thousands of prescribers and more than two years of real-world experience.
  • Positive Real-World Safety and Efficacy ExperienceManagement characterized Rezdiffra as effective across patient subtypes, well tolerated, simple to use, and supported by an increasingly well-defined safety profile across nearly 56,000 patients. Prescribers have reportedly said Rezdiffra is performing better than expected.
  • Expanding F4c OpportunityThe estimated U.S. addressable F4c population increased to 360,000 patients from the previously reported 245,000, up more than 45%. Management said expanding into F4c could double Rezdiffra's opportunity and provide patients with their first approved therapy.
  • Competitive Position in F4cManagement said competitors have modified programs, increased study sizes, and delayed timelines, with the earliest potential entrant now not expected until 2030. The company said its lead in F4c has widened.
  • Progress in MAESTRO-NASH OUTCOMESThe 845-patient, placebo-controlled, event-driven phase III MAESTRO-NASH OUTCOMES trial continues to accrue events, with a readout now anticipated in late 2027. A positive result could support an F4c indication and full approval across F2 through F4c MASH.
  • Encouraging Open-Label F4c DataIn the 122-patient open-label F4c cohort of MAESTRO-NAFLD-1, two years of Rezdiffra treatment improved MASH-related biomarkers and imaging parameters. Among patients with clinically significant portal hypertension confirmed at baseline, 65% moved to a lower-risk category.
  • New MAESTRO-CSPH Phase III TrialThe company plans to initiate MAESTRO-CSPH in the first half of 2027. The trial is planned to enroll more than 2,000 patients, enrich for clinically significant portal hypertension, generate a broad biomarker and noninvasive-data set, and produce results in the early 2030s.
  • Large Combined F4c Development ProgramAcross MAESTRO-NASH OUTCOMES and MAESTRO-CSPH, the company expects its F4c outcomes-based clinical program to include approximately 3,000 patients. Management said the two complementary trials could enable consistent clinical-benefit analyses, biomarker validation, and a more complete understanding of Rezdiffra.
  • Consistent Efficacy Across Patient SubgroupsPhase III MAESTRO-NASH data showed consistent efficacy across patients with F2 or F3 fibrosis, with or without type 2 diabetes, across BMI categories, and across common genetic variants. Rezdiffra improved fibrosis and reduced liver fat in the genetic subgroups evaluated.
  • Growing Real-World Evidence BaseResmetirom will be featured in more abstracts than any other MASH therapy at AASLD, including 13 real-world data abstracts. The largest real-world data set includes nearly 12,000 patients.
  • Expansion into Clinical Practice and Special PopulationsThe company is generating real-world evidence, studying special populations, and evaluating Rezdiffra with approved therapies for common comorbidities, including pioglitazone and SGLT2 inhibitors.
  • Broad Combination PipelineThe pipeline includes more than 10 resmetirom combination programs, six siRNA programs, and three exploratory assets. The company expects to initiate three phase II combination trials in 2027 involving ervogastat with resmetirom, MGL-2086 with resmetirom, and MGL-0795 with resmetirom.
  • Advancing siRNA and Targeted ProgramsThe company has seven total siRNA targets, including a PNPLA3 program being developed for patients homozygous for a disease-accelerating PNPLA3 mutation, along with a research collaboration with Ribocure covering six siRNA targets.
  • First Quarter of ProfitabilityMadrigal reported third-quarter net income of $55.4 million compared with a net loss of $114.2 million in the prior-year period, marking the company's first quarter of profitability.
  • Positive Operating Cash Flow and Strong LiquidityThe company has been operating cash-flow positive for the last two quarters, driven by strong revenue generation and disciplined investment. It ended the quarter with $961.8 million in cash and said it is well resourced to support Rezdiffra, advance its pipeline, and pursue business development.
  • Strong Near-Term Demand OutlookManagement said Q4 looks good, expects continued steady patient additions, and reiterated confidence in the consensus growth rate from Q3 to Q4. Management also said the underlying characteristics of 2027 are favorable, including continued patient additions, strong access, and an accelerating market.
  • Progress in EndocrinologyThe company began working with endocrinology practices in the fourth quarter of 2025 and said endocrinology practices that convert tend to go deeper faster. Some endocrinology practices have become among the company's best growth practices.
  • Resilience Despite GLP-1 CompetitionApproximately 25%-30% of patients in MAESTRO-NASH OUTCOMES were on stable GLP-1 therapy at the start of the trial. Management said the share of Rezdiffra patients using GLP-1s has remained fairly consistent, some patients have transitioned to Rezdiffra after using a GLP-1, and Wegovy has not dented Rezdiffra's growth.
  • Improving Diagnosis InfrastructureManagement cited greater disease familiarity, increased emphasis on testing in guidelines, broader access to noninvasive tests, and growing availability of scanning equipment as factors supporting diagnosis growth. Practices are beginning to formalize patient-identification pathways, including electronic-record searches.
  • Access and Contracting PositionManagement said Rezdiffra has terrific commercial access and Medicare access, with Medicare Part D contracts being negotiated for implementation in the first quarter of 2027.

MDGL Earnings History

MDGL earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)1.43--2.57――
Nov 03, 20262026 (Q3)-0.861.83-5.08136.02% (+6.91)
Jul 30, 20262026 (Q2)-2.68-1.99-1.9-4.74% (-0.09)
May 06, 20262026 (Q1)-4.23-3.25-3.322.11% (+0.07)
Feb 19, 20262025 (Q4)-0.90-2.57-2.715.17% (+0.14)
Nov 04, 20252025 (Q3)-2.29-5.08-4.92-3.25% (-0.16)
Aug 05, 20252025 (Q2)-3.55-1.90-7.173.24% (+5.20)
May 01, 20252025 (Q1)-3.75-3.32-7.3855.01% (+4.06)
Feb 26, 20252024 (Q4)-3.92-2.71-5.6852.29% (+2.97)
Oct 31, 20242024 (Q3)-6.75-4.92-5.347.87% (+0.42)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed